Tuesday, January 06, 2015 1:58:49 PM
Depression, as many of us know, is more than just a sad or melancholy mood. It’s more than just having “the blues.” Sometimes it can be a very debilitating condition that can prevent people from having productive lives – and in some cases can be a root cause of suicide and/or fatal drug overdoses.
Depression is often considered an imbalance of certain chemicals in the brain, and is treated through various therapies and anti-depressant drugs. However, the very serious level of depression – the living-in-an-abyss type of depression that was behind the recent death of actor and comedian Robin Williams (also known as Major Depressive Disorder, or MDD) – has been very difficult to treat effectively. There has been a trade-off with some therapies – there are some strong anti-depressants in the market, but most have side effects that can be dangerous in their own right – perhaps more so than the depression itself. VistaGen Therapeutics, Inc. (OTCQB: VSTA) is looking to fill this very important mental-health gap with its own potential new antidepressant therapy known as AV-101.
VistaGen’s AV-101 has gone through the initial Phase 1 clinical development focused on human safety and the company is now working toward a significant Phase 2 clinical trial of AV-101 in collaboration with the U.S. National Institutes of Health (NIH). The NIH previously awarded the company nearly $9 million for its preclinical and Phase 1 development programs, and the company expects the NIH to sponsor and conduct the impending Phase 2 efficacy study. VistaGen believes AV-101 is a potential new generation antidepressant with a novel mechanism of action to address MDD more rapidly and with fewer and less-severe side effects than other depression therapies currently being used.
With a successful Phase 2 trial which is expected to be completed by the end of 2015, there could be some significant momentum for VistaGen Therapeutics in the mental-health sector, with AV-101 as a novel potential therapy for MDD and other similar mood disorders that affect millions of Americans. Robin Williams’ sad and tragic death has brought MDD more prominently into the forefront, and it will be therapies like AV-101 that will be watched more readily as mental-health professionals look to encourage more diagnoses of depression and other mood disorders so they can be treated early and aggressively. This is an environment for VistaGen Therapeutics to be in the spotlight.
For more information, visit www.vistagen.com
Recent VTGN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 09:00:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 09:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 09:00:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/10/2024 09:00:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2024 08:07:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:53:06 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:49:59 PM
- Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update • Business Wire • 08/13/2024 08:21:00 PM
- Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024 • Business Wire • 08/06/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2024 08:27:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2024 08:34:14 PM
- Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine • Business Wire • 07/09/2024 12:30:00 PM
- Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year • Business Wire • 06/27/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:27:53 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/11/2024 08:27:09 PM
- Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update • Business Wire • 06/11/2024 08:20:00 PM
- U.S. Index Futures Fall Ahead of Federal Reserve Policy Meeting, Crude Oil Prices Decline • IH Market News • 06/11/2024 11:07:13 AM
- Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024 • Business Wire • 06/07/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:10:11 PM
- Vistagen to Present at the Jefferies Global Healthcare Conference • Business Wire • 05/29/2024 12:30:00 PM
- Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference • Business Wire • 05/23/2024 12:30:00 PM
- Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference • Business Wire • 05/07/2024 12:30:00 PM
- Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue • Business Wire • 04/25/2024 12:30:00 PM
- Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference • Business Wire • 04/09/2024 12:30:00 PM
- Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 • Business Wire • 04/01/2024 12:30:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM